BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17594720)

  • 1. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.
    Lin EH; Hassan M; Li Y; Zhao H; Nooka A; Sorenson E; Xie K; Champlin R; Wu X; Li D
    Cancer; 2007 Aug; 110(3):534-42. PubMed ID: 17594720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases.
    Mehra N; Penning M; Maas J; Beerepoot LV; van Daal N; van Gils CH; Giles RH; Voest EE
    Clin Cancer Res; 2006 Aug; 12(16):4859-66. PubMed ID: 16914572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of peripheral blood CD133 mRNA in identifying metastasis and in predicting recurrence of patients with clear cell renal cell carcinoma.
    Feng G; Jiang F; Pan C; Pu C; Huang H; Li G
    Urol Oncol; 2014 Jan; 32(1):44.e9-14. PubMed ID: 24054866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD133 mRNA expression and microsatellite instability in colorectal carcinoma.
    Huh JW; Park YS; Lee JH; Kim HR; Shin MG; Kim YJ
    J Surg Oncol; 2010 Dec; 102(7):765-70. PubMed ID: 20872808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
    Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
    Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
    Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
    Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer.
    Dome B; Timar J; Dobos J; Meszaros L; Raso E; Paku S; Kenessey I; Ostoros G; Magyar M; Ladanyi A; Bogos K; Tovari J
    Cancer Res; 2006 Jul; 66(14):7341-7. PubMed ID: 16849585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
    Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
    Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.
    Cortes-Dericks L; Galetta D; Spaggiari L; Schmid RA; Karoubi G
    Eur J Cardiothorac Surg; 2012 Jun; 41(6):e173-81. PubMed ID: 22529186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery.
    Nakamura K; Iinuma H; Aoyagi Y; Shibuya H; Watanabe T
    Oncology; 2010; 78(5-6):309-15. PubMed ID: 20616575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
    Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
    Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph node CXCL17 messenger RNA: A new prognostic biomarker for colon cancer.
    Rashad Y; Olsson L; Israelsson A; Öberg Å; Lindmark G; Hammarström ML; Hammarström S; Sitohy B
    Tumour Biol; 2018 Sep; 40(9):1010428318799251. PubMed ID: 30198422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma.
    Yu JW; Zhang P; Wu JG; Wu SH; Li XQ; Wang ST; Lu RQ; Ni XC; Jiang BJ
    J Exp Clin Cancer Res; 2010 Nov; 29(1):141. PubMed ID: 21054902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of carcinoembryonic antigen mRNA in peritoneal lavage by the transcription-reverse transcription concerted method indicates poor prognosis in patients with stage II and III colon cancer.
    Murono K; Kazama S; Yamaguchi H; Kawai K; Ishihara S; Sunami E; Kitayama J; Satoh Y; Kurihara M; Yatomi Y; Watanabe T
    Surgery; 2015 Feb; 157(2):322-30. PubMed ID: 25311262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood mononuclear CD133 mRNA levels correlates with response to treatment in patients with gastrointestinal stromal tumors.
    Deng Y; Hassan MM; Mo J; Lin EH
    PLoS One; 2013; 8(2):e55520. PubMed ID: 23408993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis.
    Gill S; Haince JF; Shi Q; Pavey ES; Beaudry G; Sargent DJ; Fradet Y
    Clin Colorectal Cancer; 2015 Jun; 14(2):99-105. PubMed ID: 25619805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
    Pohl A; El-Khoueiry A; Yang D; Zhang W; Lurje G; Ning Y; Winder T; Hu-Lieskoven S; Iqbal S; Danenberg KD; Kahn M; Teo JL; Shriki J; Stebbing J; Lenz HJ
    Pharmacogenomics J; 2013 Apr; 13(2):173-80. PubMed ID: 22231565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.